INTRODUCTION
============

The critically ill patient is usually dependent on mechanical ventilation enabled by prostheses, including the endotracheal tube and tracheostomy cannula. Both devices contain a cuff, which is a balloon that seals the lower airways during mechanical ventilation.^([@r01])^ The cuff should be examined every four hours, and its inflation should be maintained at an ideal pressure of 20 to 30 cmH~2~O to avoid bronchoaspiration (when using reduced pressure) and tracheal wall injury (when using increased pressure).^([@r02]-[@r04])^

There are two types of cuff: the high-volume, low-pressure cuff and the low-volume, high-pressure cuff. The high-volume, low-pressure cuff, which is the oldest type of cuff and is also called \"red rubber,\" has a small contact area with the trachea when inflated and deforms into a circular shape. Thus, prolonged use of this device leads to ischemia and, consequently, tracheal wall injury. However, the high-volume, low-pressure cuff has a lower cost, provides stronger sealing of the trachea, and is effective against bronchoaspiration. The low-volume, high-pressure cuff is a more recently developed device that has a thin wall, which (when inflated) easily adapts to the irregular edges of the tracheal wall, preventing injuries.^([@r05])^

However, the cylindrically shaped, high-volume, low-pressure cuff does not fully protect the airways from aspiration of secretions, food, and gastric contents^([@r06])^ because it acts as a reservoir of oropharyngeal secretions,^([@r07],[@r08])^ as upper airway secretions, saliva, and food that are above the cuff tend to drip from the sides of the trachea^([@r06]-[@r08])^ and through microchannels formed by the cuff material collapsing upon itself.^([@r09]-[@r11])^ These events lead to sustained bronchoaspiration of accumulated peri-cuff materials,^([@r06]-[@r08])^ which is a process called microaspiration. Microaspiration, combined with bacterial colonization of the aerodigestive tract, is the main cause of ventilator-associated pneumonia (VAP).^([@r12],[@r13])^

VAP is defined as inflammation of the lung parenchyma that is caused by infectious agents 48 to 72 hours after orotracheal intubation and the onset of mechanical ventilation.^([@r14])^ VAP is typically the most frequent infection in patients admitted to the intensive care unit (ICU),^([@r15])^ representing approximately 60% of nosocomial infections^([@r16])^ and increasing the duration of hospitalization, thereby increasing hospital costs.^([@r14])^ Indeed, VAP is the leading cause of morbidity and mortality among critically ill patients.^([@r17])^

Although the classification of VAP has been recently questioned, the disease is categorized as two types: early-onset (developing up to four days after the initiation of mechanical ventilation) and late-onset (developing after the fifth day of mechanical ventilation).^([@r16],[@r18])^ Early-onset VAP is usually caused by microaspiration of bacteria colonizing the oropharynx (Gram-positive cocci and *Haemophilus influenza*)^([@r14])^ and usually yields a better prognosis because the disease-causing microorganisms are sensitive to antibiotics.^([@r18])^ Late-onset VAP is usually caused by nosocomial organisms, including *Pseudomonas aeruginosa*, *Stenotrophomonas maltophilia*, and methicillin-resistant *Acinetobacter*and*Staphylococcus aureus*species^([@r14])^ (multi-resistant microorganisms), which are associated with increased morbimortality.^([@r18])^

The concept of preventing bronchoaspiration (and thereby, VAP) is based on reducing the amount of the aspirate, among other factors.^([@r06])^ A possibly preventive method is the suction of pulmonary secretions,^([@r19])^ which is usually performed via an open or closed suction system.^([@r20])^ In the literature, both tracheal suction systems have similar effects on the development of VAP, but these systems fail to achieve suction of secretions that accumulate in the subglottic space proximal to the cuff.^([@r20])^ New endotracheal tubes and tracheostomy cannulae have been developed, which have a dorsal lumen that facilitates continuous or intermittent suction of the subglottic space, thus targeting the leakage of peri-cuff secretions.^([@r15])^

Several studies have demonstrated that aspiration of subglottic secretions (ASS) using a device with a dorsal suction lumen above the cuff of the endotracheal tube delays the onset and reduces the incidence of VAP.^([@r15],[@r21]-[@r25])^

METHODS
=======

The literature review was conducted using the following electronic databases: MEDLINE (Medical Literature Analysis and Retrieval System Online), PubMed (Public MEDLINE), Cochrane, SciELO (Scientific Electronic Library Online), and LILACS (Latin-American and Caribbean Health Sciences Literature Database) for the period from 1986 to 2011. The keywords used were \"subglottic secretions drainage,\" \"subglottic aspiration,\" and \"ventilator-associated pneumonia\".

RESULTS
=======

The seven relevant studies that were found are listed in [table 1](#t01){ref-type="table"}.

###### 

Summary of results

  **Author**                   **Sample**   **Study design**                                       **Type of ICU**    **Time of**                   **Ventilatory**                                                                         **Control of cuff**                                                        **ASS method**                       **Use of**   **Results**
  ---------------------------- ------------ ------------------------------------------------------ ------------------ ----------------------------- --------------------------------------------------------------------------------------- -------------------------------------------------------------------------- ------------------------------------ ------------ -------------------------------------------------------------------------------------------------
  Vallés et al.^([@r21])^      153          Double-blind, randomized, controlled study             Medical-surgical   \>72 hours                    OTI with supra-cuff device (open versus closed dorsal suction port)                     \>20 mmHg, measured every four hours                                       Continuous                           No           Reduces early-onset VAP incidence by 43.3%
                                                                                                                                                                                                                                                                                                                                                                         
  Kollef et al.^([@r26])^      343          Prospective clinical trial                             Cardiothoracic     Shortly after heart surgery   OTI with supra-cuff device (open versus closed dorsal suction port dorsal)              Not performed                                                              Intermittent                         Yes          Delayed VAP progression in the ASS group
                                                                                                                                                                                                                                                                                                                                                                         
  Smulders et al.^([@r22])^    150          Randomized clinical trial                              General            \>72 hours                    OTI with supra-cuff device versus conventional OTI                                      Cuff inflated in an empirical manner; pressure measured every four hours   Intermittent                         No           10% of patients who developed VAP: 4% from the ASS group and 16% from the control group
                                                                                                                                                                                                                                                                                                                                                                         
  Bouza et al.^([@r15])^       690          Prospective randomized clinical trial                  Cardiothoracic     \>48 hours                    OTI with supra-cuff device versus conventional OTI TQT maintains standard used in OTI   20 to 30 mmHg, measured at every shift                                     Continuous                           Yes          Reduces VAP incidence and the length of MV and ICU stay, in addition to reducing hospital costs
                                                                                                                                                                                                                                                                                                                                                                         
  Lacherade et al.^([@r25])^   333          Multicenter randomized and controlled clinical trial   Medical-           \>48 hours                    OTI with supra-cuff device versus conventional OTI                                      20 to 30 cmH~2~O, measured every three hours                               Intermittent (manual with syringe)   Yes          Reduces early- and late-onset VAP incidence
                               surgical                                                                                                                                                                                                                                                                                                                                  
  Dezfulian et al.^([@r23])^   896          Systematic meta-analysis                                                                                                                                                                                                                                                                                                     Reduces the risk of early-onset VAP by 50%. Reduces the days of MV and ICU stay
                                                                                                                                                                                                                                                                                                                                                                         
  Coffman et al.^([@r24])^                  Prospective study                                                                                       Anatomical model: TQT with supra-cuff device versus conventional TQT                                                                                               Absent Continuous Intermittent                    Reduces saliva suction. Continuous ASS appears more effective

CU - intensive care unit; MV - mechanical ventilation; VAP - ventilator-associated pneumonia; ASS - aspiration of subglottic secretions; OTI - orotracheal intubation; TQT - tracheotomy.

Vallés et al.^([@r21])^ demonstrated that using ASS in intubated patients reduces the VAP incidence by 43.4%. However, there was no significant difference in VAP incidence between the groups given continuous ASS versus conventional aspiration, after the first week of mechanical ventilation. According to the authors, these results were possibly due to the putative decrease in the volume of oropharyngeal secretions aspirated from the interior of the bronchial tract by ASS and to the putative decrease in inoculum size. Thus, the minimum inoculum required to induce early-onset pneumonia is larger than the inoculum required toinduce late-onset pneumonia. Consequently, reduction of the inoculum size might explain the delayed progression of late-onset pneumonia and reduced early-onset pneumonia in patients undergoing ASS. Finally, the authors concluded that the incidence of nosocomial pneumonia in mechanically ventilated patients can be significantly reduced using this simple method, which reduces chronic microaspiration through the cuff of endotracheal tubes.

According to Kollef et al.,^([@r26])^ VAP progression is delayed in patients subjected to ASS. However, no difference was found in the overall rate of VAP between patients submitted to intermittent ASS and those who were not. The explanation of the authors for the discrepancy between their results and other studies was the small sample, the investigation of only one ICU, and the randomization method, which was based on the participants\' birthdays. However, these arguments are flawed because the study utilized a larger sample than did other studies,^([@r21],[@r22],[@r25])^ several of which were also conducted at only one institution,^([@r15],[@r21],[@r22])^ and the randomization efficiently generated groups of patients without significant differences. However, Kollef et al.^([@r26])^ failed to mention having performed measurements of the cuff pressure, which could indeed explain the lack of significant differences regarding the use of ASS. Therefore, the authors conclude that ASS can be safely administered in patients undergoing heart surgery and that the occurrence of VAP can be significantly delayed in these patients via an easily applied technique.

Smulders et al.^([@r22])^ determined that VAP can be prevented by ASS in mechanically ventilated patients for more than three days and recommended incorporation of the technique into the routine care of such patients.

Dezfulian et al.^([@r23])^ found that based on the bacteriological etiology, ASS reduces the risk of VAP by approximately 50% and delays progression of VAP (compared with the control group) in addition to reducing the risk of early-onset pneumonia. Furthermore, patients submitted to ASS remain fewer days on mechanical ventilation and spend less time in the ICU. However, the length of hospital stay and mortality does not significantly differ between the groups. Thus, the authors found that ASS primarily reduces early-onset VAP and argued that it is unclear why this result did not hold for late-onset pneumonia. Dezfulian et al.^([@r23])^ also mentioned the existence of few ASS-related complications and the occurrence of dorsal lumen obstruction in the tube with a supra-cuff device due to aspirated secretions, which caused the device to stop functioning; however, there were no adverse effects in the patient because the orotracheal tube later merely became similar to a conventional endotracheal tube. Thus, ASS appears to be effective in preventing early-onset VAP among patients who are ventilated for more than 72 hours.

Bouza et al.^([@r15])^ observed a significant reduction in VAP incidence in the continuous ASS group and a reduction in the density of VAP incidence. The length of stay in the ICU and the duration of mechanical ventilation are also lower in patients with continuous ASS, and there is a significant reduction in the daily dose of antibiotics in this group. Thus, continuous aspiration should be included in the protocol used to reduce the incidence and outcomes of VAP, at least in populations of patients undergoing heart surgery.

Lacherade et al.,^([@r25])^ in their multicenter randomized study, demonstrated that intermittent ASS reduces the incidence of VAP, including late-onset VAP without any adverse effects. The authors suggest that the reduction in the late-onset VAP incidence may have been revealed due to the large sample size, the use of prolonged mechanical ventilation (more than five days), and the low early-onset VAP incidence (use of prophylactic antibiotic treatment), as more patients could be evaluated for an extended period.

Few studies assess the effectiveness of tracheotomy cannulae combined with a supra-cuff device. Of the studies found, only Coffman et al.^([@r24])^ observed that aspiration of saliva is reduced by using a subglottic suction port, and continuous aspiration appears to be more effective than intermittent aspiration. These results suggest a potential decrease in the risk of aspiration in chronically ventilated patients when a tracheotomy tube with suction is used. However, the performance is expected to be similar to that of an orotracheal tube with the same device.

Several studies mention the cost of using orotracheal tubes with a supra-cuff suction device. However, Bouza et al.^([@r15])^ reported that ASS ensures a considerable reduction in hospital costs because the savings from purchasing antibiotics is much higher than the costs associated with an orotracheal tube with the supra-cuff device. Shorr and O\'Malley^([@r17])^ demonstrated that tubes with the supra-cuff device may lead to significant savings if regularly used in all emergency orotracheal intubations. Although these devices are more expensive than traditional orotracheal tubes, this difference is offset by the high costs associated with VAP.

Suction of subglottic secretions provides significant clinical value. However, using bronchoscopy, Dragoumanis et al.^([@r27])^ observed a suction-lumen malfunction in 19 out of 40 patients (48%); 17 cases (43%) were attributed to blockage of the subglottic suction port (due to suction of the tracheal mucosa), one case of obstruction was caused by thick secretions, and one case was indeterminate. Thus, the authors argued that a negative pressure of less than 20 mmHg favors the prolapse of tracheal mucosa into the subglottic suction port, triggering local ischemia in the tracheal mucosa and exposing the patient to an elevated risk of tracheal injury.

According to Bouza et al.,^([@r15])^ the cuff pressure should be assessed, and the suction lumen should be maintained permeable. The authors recommend instilling 10 mL of sterile water into the subglottic lumen to keep it patent. If an obstruction exists, then permeability should be restored with an air bolus through the subglottic lumen. Consequently, no continuous ASS-related complications were observed in this study. Moreover, there were no cases of lumen obstruction, as the aforementioned protocol was maintained.

In 2005, a design change in the orotracheal tube with the supra-cuff device was introduced to solve issues regarding tracheal injury and suction-lumen obstruction by thick secretions. To this end, the subglottic suction port was moved nearest the cuff, preventing suction of the tracheal mucosa, and the suction port and the lumen were extended to prevent obstruction by thick secretions. Consequently, the device had a greater external diameter than did the conventional orotracheal tube and was most likely stiffer. However, the effects of the new design on the failure rate of subglottic suction or on the occurrence of laryngeal/tracheal injuries have not yet been assessed.^([@r11])^

Another issue is the mode of suction of subglottic secretions. Smulders et al.^([@r22])^ restricted the use of intermittent ASS because continuous suction with 100 mmHg can damage the tracheal wall.

Thus, only in the study by Kollef et al.^([@r26])^ there were no significant difference in VAP incidence between the groups subjected to ASS and the group undergoing conventional care. The remaining studies demonstrated a reduced VAP incidence with the use of ASS combined with cuff pressure control.^([@r15],[@r21]-[@r23],[@r25])^

Additionally, although ASS yields few instances of decreased duration of mechanical ventilation and ICU/hospital stay^([@r15],[@r23])^ and is ineffective in decreasing mortality,^([@r15],[@r21]-[@r23],[@r25],[@r26])^ the technique efficiently reduces early-onset VAP incidence,^([@r15],[@r21]-[@r23],[@r25])^ with few adverse effects being reported.^([@r15],[@r23],[@r27])^ Furthermore, ASS effectively reduces VAP-related hospital costs^([@r15],[@r17])^ and is thus supported by the guidelines of three of four agencies: the Centers for Disease Control and Prevention (2004), the Canadian Critical Care Society (2004), the American Thoracic Society, and the Infectious Disease Society (2005).^([@r28])^ Nevertheless, cannulae combined with supra-cuff suction devices are only occasionally used, despite recommendation by these agencies\' guidelines. Gentile and Siobal^([@r11])^ have stated that among other aspects, the inconsistent methodologies leading to heterogeneous patient populations among studies and the lack of standard VAP diagnosis criteria could affect study results, sustaining disagreement on the strength of evidence regarding the method\'s effectiveness. Another factor that should be addressed is the method of using supra-cuff devices; though intermittent suction is less harmful to the tracheal mucosa, further studies are needed to define how it should be used (i.e., the negative pressure value, suction time, and intervals). Future studies on the impact of using the supra-cuff device in tracheostomized patients are still necessary in addition to investigations assessing the effectiveness of the new design of the orotracheal tube with a supra-cuff device.

CLOSING REMARKS
===============

Cannulae combined with supra-cuff suction devices enable the suction of subglottic secretions, which is beneficial to critically ill patients because these devices reduce VAP incidence and, consequently, hospital costs-with no large-scale adverse effects. However, other forms of VAP prevention must be combined with use of the orotracheal tube with a supra-cuff device, as the device alone has not proven effective in reducing the duration of mechanical ventilation, ICU/hospital stays, and mortality rates.
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